Keyword: Axovant Sciences
Axovant has clinical readouts from its switch into gene therapy after failed endeavors in Alzheimer’s—and the initial data look encouraging.
Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.
Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.
Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
Axovant Sciences has renamed itself Axovant Gene Therapies to put a seal on its bid to become a player at the cutting edge of genetic medicine.
Since Pavan Cheruvu took Axovant’s helm in February 2018, the company has been plugging away at becoming a gene therapy player.
The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.
Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia.
Abeona fires CEO Carsten Thiel; MHRA CEO to leave in wake of Brexit; Lilly CMO to lead Brickell Bio; and Janssen's discovery head joins Incyte.
After refocusing on gene therapy, Axovant is appointing five new executives to posts ranging from clinical development to commercial operations.
